B. Goldman

发表

SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin.

I. Thompson, C. Tangen, W. Sakr, 2013, The Journal of urology.

A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517

L. Rimsza, R. Fisher, S. Forman, 2012, Leukemia & lymphoma.

Biased hormonal therapy duration analysis makes results uninterpretable.

I. Thompson, C. Tangen, G. Swanson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy

H. Grossman, G. Sonpavde, V. Speights, 2009, Cancer.

Cetuximab as Second-Line Therapy in Patients with Metastatic Esophageal Adenocarcinoma: A Phase II Southwest Oncology Group Study (S0415)

H. Lenz, C. Blanke, Wu Zhang, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Modeling the Relationship between Progression-Free Survival and Overall Survival: The Phase II/III Trial

M. LeBlanc, L. Baker, A. Schott, 2013, Clinical Cancer Research.

Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy.

C. Ryan, D. Petrylak, E. Crawford, 2008, Clinical genitourinary cancer.

Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies.

G. Salles, J. Friedberg, L. Rimsza, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.

C. Tangen, E. Crawford, E. Klein, 2007, The Journal of urology.

Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.

C. Tangen, E. Crawford, R. DiPaola, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219).

David C. Smith, C. Tangen, E. Crawford, 2009, The Journal of urology.

Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes.

S. Dakhil, C. Ryan, E. Crawford, 2008, Clinical genitourinary cancer.

Oxaliplatin (OXP) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to surgery (S) for potentially curable esophageal adenocarcinoma (EA): A Southwest Oncology Group (SWOG) phase II trial with molecular correlates (S0356).

H. Lenz, C. Corless, C. Blanke, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cetuximab as second-line therapy in patients with metastatic esophageal cancer: A phase II Southwest Oncology Group Study

H. Lenz, L. Leichman, C. Blanke, 2008 .

Chemoradiation of resected gastric cancer: A 10-year follow-up of the phase III trial INT0116 (SWOG 9008).

J. Ajani, D. Haller, J. Jessup, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sorafenib plus interferon-α2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412.

C. Ryan, H. Drabkin, T. Beer, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SWOG S0354: A phase II trial of CNTO328, a monoclonal antibody against interleukin-6 (IL-6), in chemotherapy pretreated patients (pts) with castration- resistant prostate cancer (CRPC).

J. Pinski, I. Thompson, T. Dorff, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study.

L. Rimsza, R. Fisher, R. Braziel, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

MYC Protein Expression, but Not High Grade Morphology, Is Associated with Poor Outcome in Non-Burkitt Diffuse Aggressive B-Cell Lymphomas: A SWOG S9704 Correlative Study

L. Rimsza, R. Fisher, M. Leblanc, 2012 .

MUM1 Expression in Follicular Lymphoma Is a Poor Prognostic Marker in Patients Treated with Immunochemotherapy (SWOG 9800/9911) but Not Chemotherapy Alone (SWOG 8809): A Southwest Oncology Group Correlative Science Study

L. Rimsza, R. Fisher, D. Maloney, 2008 .

Aneusomy for detection of bladder cancer recurrence: a Southwest Oncology Group study.

C. Tangen, M. Slovak, D. Wood, 2007, Cancer genetics and cytogenetics.

S0413: A phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer

H. Lenz, C. Fenoglio-Preiser, C. Blanke, 2007 .

A phase II study of PXD101 (belinostat) in relapsed and refractory aggressive B-cell lymphomas (rel/ref ABCL): SWOG S0520.

L. Rimsza, R. Fisher, T. Miller, 2012 .

Use of prostate-specific antigen progression (PSA-P) to predict overall survival (OS) in patients (pts) with metastatic prostate cancer (PC): Data from S9346 and S9916

C. Tangen, E. Crawford, C. Higano, 2008 .

Vorinostat (Suberoylanilide Hydroxamic Acid) in Relapsed or Refractory Hodgkin Lymphoma: SWOG 0517.

L. Rimsza, R. Fisher, S. Forman, 2007 .

S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma.

Charles R. Thomas, H. Lenz, C. Corless, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer

J. Pinski, I. Thompson, T. Dorff, 2010, Clinical Cancer Research.

Patterns of cervical coinfection with multiple human papilloma virus types in a screening population in Denmark.

E. Lynge, M. Rebolj, S. Preisler, 2013, Vaccine.

Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.

J. Ajani, D. Haller, C. Blanke, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dual blockade of epidermal growth factor receptor and insulin‐like growth factor receptor–1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727)

P. Philip, H. Lenz, C. Blanke, 2014, Cancer.

Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group.

C. Tangen, C. Ryan, P. Mack, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.

A. Khorana, P. Philip, C. Fenoglio-Preiser, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cetuximab Plus Cisplatin, Irinotecan, and Thoracic Radiotherapy as Definitive Treatment for Locally Advanced, Unresectable Esophageal Cancer: A Phase-II Study of The SWOG (S0414)

Charles R. Thomas, H. Lenz, J. Abbruzzese, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer

H. Lenz, W. Zhang, C. Fenoglio-Preiser, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer.

S. Lippman, P. Philip, C. Moinpour, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone

L. Rimsza, R. Fisher, T. Miller, 2012, Haematologica.

Genetic polymorphisms in oxidative stress‐related genes are associated with outcomes following treatment for aggressive B‐cell non‐Hodgkin lymphoma

J. Cerhan, L. Rimsza, R. Fisher, 2014, American journal of hematology.

Clinical Significance of MYC Expression and/or “High-grade” Morphology in Non-Burkitt, Diffuse Aggressive B-cell Lymphomas: A SWOG S9704 Correlative Study

L. Rimsza, R. Fisher, M. Leblanc, 2014, The American journal of surgical pathology.

The prognostic value of hemoglobin change after initiating androgen‐deprivation therapy for newly diagnosed metastatic prostate cancer

C. Tangen, E. Crawford, M. Hussain, 2006, Cancer.